König F, Wolfersdorf M
Department of Psychiatry I, University of Ulm, Ravensburg, Germany.
Pharmacopsychiatry. 1997 May;30(3):93-6. doi: 10.1055/s-2007-979489.
In an open trial, a combination therapy with 300 mg moclobemide was instituted after adjustment to a classical tricyclic or tetracyclic antidepressant in a group of 23 previously therapy-resistant depressive inpatients (pretreatment with two biochemically different antidepressants over a period of at least 5 weeks with sufficient doses). In 13 patients (53.9%) a significant improvement on the Hamilton Depression Scale (24-item version) of at least 50% was achieved. The improvement in the BPRS was also significant. On the basis of the present findings, a combination therapy with the reversible MAO-inhibitor moclobemide represents an efficacious regimen for therapy-resistant depressions, with low side-effects. After this pilot study, further controlled studies are necessary.
在一项开放性试验中，对一组23名先前对治疗有抵抗性的抑郁住院患者（在至少5周的时间内使用两种生化特性不同的抗抑郁药进行足量预处理），在调整至经典三环或四环抗抑郁药治疗后，采用300毫克吗氯贝胺进行联合治疗。13名患者（53.9%）在汉密尔顿抑郁量表（24项版本）上有至少50%的显著改善。简明精神病评定量表（BPRS）的改善也很显著。基于目前的研究结果，可逆性单胺氧化酶抑制剂吗氯贝胺联合治疗是一种治疗抵抗性抑郁症的有效方案，且副作用小。在这项初步研究之后，还需要进一步的对照研究。
